BDTX 4876
Alternative Names: BDTX-4876Latest Information Update: 05 Mar 2024
At a glance
- Originator Black Diamond Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Achondroplasia; Solid tumours
Most Recent Events
- 15 Feb 2024 BDTX 4876 is available for licensing as of 15 Feb 2024. https://www.blackdiamondtherapeutics.com/pipeline-programs/bdtx-4876
- 15 Feb 2024 Preclinical trials in Achondroplasia in USA (PO) (Black Diamond Therapeutics pipeline, February 2024)
- 15 Feb 2024 Preclinical trials in Solid tumours in USA (PO) (Black Diamond Therapeutics pipeline, February 2024)